Moderna (NASDAQ:MRNA) Receives “Hold” Rating from Needham & Company LLC

Moderna (NASDAQ:MRNA)‘s stock had its “hold” rating reiterated by Needham & Company LLC in a research note issued on Thursday, Benzinga reports.

Other analysts have also recently issued reports about the company. Canaccord Genuity Group boosted their price target on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research report on Friday, February 23rd. JPMorgan Chase & Co. dropped their price target on Moderna from $93.00 to $90.00 and set a “neutral” rating for the company in a research report on Friday, December 1st. HSBC reiterated a “reduce” rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target for the company in a research report on Tuesday, January 2nd. Finally, Canaccord Genuity Group began coverage on Moderna in a research report on Wednesday, November 29th. They set a “hold” rating and a $82.00 price target for the company. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $129.82.

Moderna Trading Up 3.0 %

Shares of MRNA stock opened at $110.59 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. The company has a market cap of $42.34 billion, a price-to-earnings ratio of -8.91 and a beta of 1.60. The stock has a 50 day simple moving average of $98.79 and a 200-day simple moving average of $93.49. Moderna has a 1-year low of $62.55 and a 1-year high of $163.24.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.78) by $1.33. The business had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The business’s quarterly revenue was down 44.9% on a year-over-year basis. During the same period in the prior year, the company posted $3.61 EPS. On average, equities research analysts expect that Moderna will post -7.48 EPS for the current fiscal year.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 647 shares of the firm’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the transaction, the chief financial officer now directly owns 4,300 shares in the company, valued at approximately $406,651. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO James M. Mock sold 772 shares of Moderna stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $109.75, for a total value of $84,727.00. Following the completion of the transaction, the chief financial officer now owns 3,632 shares in the company, valued at approximately $398,612. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James M. Mock sold 647 shares of Moderna stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the transaction, the chief financial officer now owns 4,300 shares of the company’s stock, valued at approximately $406,651. The disclosure for this sale can be found here. Insiders sold 50,021 shares of company stock worth $5,211,442 in the last three months. 15.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Moderna

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Cim Investment Management Inc. boosted its stake in shares of Moderna by 4.2% in the 1st quarter. Cim Investment Management Inc. now owns 2,139 shares of the company’s stock valued at $329,000 after buying an additional 86 shares during the period. Cetera Advisor Networks LLC lifted its stake in Moderna by 0.5% during the fourth quarter. Cetera Advisor Networks LLC now owns 17,195 shares of the company’s stock worth $3,088,000 after purchasing an additional 87 shares during the last quarter. Ancora Advisors LLC lifted its stake in Moderna by 41.2% during the first quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock worth $51,000 after purchasing an additional 96 shares during the last quarter. Sunbelt Securities Inc. lifted its stake in Moderna by 7.5% during the first quarter. Sunbelt Securities Inc. now owns 1,428 shares of the company’s stock worth $211,000 after purchasing an additional 100 shares during the last quarter. Finally, Allworth Financial LP lifted its stake in Moderna by 6.5% during the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after purchasing an additional 101 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.